X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs VENUS REMEDIES - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA VENUS REMEDIES ABBOTT INDIA/
VENUS REMEDIES
 
P/E (TTM) x 36.3 -1.2 - View Chart
P/BV x 9.4 0.1 10,486.8% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ABBOTT INDIA   VENUS REMEDIES
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
VENUS REMEDIES
Mar-18
ABBOTT INDIA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs6,110126 4,853.1%   
Low Rs3,99661 6,540.1%   
Sales per share (Unadj.) Rs1,552.2301.8 514.3%  
Earnings per share (Unadj.) Rs188.8-24.9 -759.2%  
Cash flow per share (Unadj.) Rs196.42.5 7,719.3%  
Dividends per share (Unadj.) Rs55.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs796.6293.3 271.6%  
Shares outstanding (eoy) m21.2512.34 172.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.30.3 1,050.7%   
Avg P/E ratio x26.8-3.8 -711.9%  
P/CF ratio (eoy) x25.736.7 70.0%  
Price / Book Value ratio x6.30.3 1,989.7%  
Dividend payout %29.10-   
Avg Mkt Cap Rs m107,3761,154 9,306.4%   
No. of employees `0003.30.9 359.1%   
Total wages/salary Rs m3,937393 1,001.5%   
Avg. sales/employee Rs Th9,929.34,026.1 246.6%   
Avg. wages/employee Rs Th1,185.1425.0 278.9%   
Avg. net profit/employee Rs Th1,207.7-331.8 -364.0%   
INCOME DATA
Net Sales Rs m32,9853,724 885.7%  
Other income Rs m1,17023 5,199.6%   
Total revenues Rs m34,1553,747 911.6%   
Gross profit Rs m5,245395 1,328.5%  
Depreciation Rs m162338 47.9%   
Interest Rs m38354 10.8%   
Profit before tax Rs m6,215-275 -2,257.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,20332 6,970.6%   
Profit after tax Rs m4,012-307 -1,307.3%  
Gross profit margin %15.910.6 150.0%  
Effective tax rate %35.4-11.5 -308.8%   
Net profit margin %12.2-8.2 -147.6%  
BALANCE SHEET DATA
Current assets Rs m22,6552,638 858.9%   
Current liabilities Rs m6,6812,305 289.9%   
Net working cap to sales %48.48.9 541.5%  
Current ratio x3.41.1 296.3%  
Inventory Days Days65135 47.8%  
Debtors Days Days2946 62.9%  
Net fixed assets Rs m8354,871 17.2%   
Share capital Rs m213123 172.2%   
"Free" reserves Rs m16,7153,496 478.2%   
Net worth Rs m16,9283,619 467.7%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m24,1627,509 321.8%  
Interest coverage x163.70.2 73,412.4%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.40.5 275.2%   
Return on assets %16.80.6 2,655.4%  
Return on equity %23.7-8.5 -279.5%  
Return on capital %36.91.6 2,334.9%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m3690-   
Fx outflow Rs m3,807517 737.0%   
Net fx Rs m-3,438-517 665.6%   
CASH FLOW
From Operations Rs m1,527514 296.9%  
From Investments Rs m-2,148-123 1,745.2%  
From Financial Activity Rs m-1,024-387 264.6%  
Net Cashflow Rs m-1,6464 -39,181.0%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 0.2 4,388.9%  
FIIs % 0.1 0.6 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 66.4 25.8%  
Shareholders   18,270 20,121 90.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   DR. DATSONS LABS  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  BIOCON   

Compare ABBOTT INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Hit Record High as Exit Polls Predict NDA Win; Sensex Ends 1,421 Points Higher(Closing)

Indian share markets witnessed huge buying interest today. The benchmark indices opened gap-up after Exit Polls for the Lok Sabha Elections 2019.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

A 10-Bagger in Just 6 Years! The Rebirth of India Will Create More Big Winners Like This(The 5 Minute Wrapup)

May 7, 2019

How a niche tech startup battled all odds to eventually become a 10 bagger.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


May 20, 2019 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - IPCA LABS COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS